|
Case
Study Value
of Innovative Medicines Educational Series Situation:
The
pharmaceutical industry’s trade association needed expert assistance in
developing a series of documents explaining how increased spending on specific
diseases was the result of new treatments that both improved clinical outcomes
and reduced spending on other healthcare services, such as hospitalizations.
These documents were needed to respond to critics who were attacking
the industry’s pricing practices and the US healthcare system's increased spending on pharmaceuticals.
Actions:
Researched
and wrote sections about the clinical value and the science behind the
development of new treatments for diabetes,
high cholesterol and rheumatoid
arthritis.
Researched and wrote the entire document explaining how the development
of new treatments for depression, bipolar disorder, and schizophrenia
had:
 |
Changed
the clinical care for these conditions |
|
Dramatically
improved outcomes |
|
Produced
value for the healthcare system because of the increased use
of medicines to treat these conditions |
|
Been
possible because of new scientific insights that guided individual
company research and development activities |
Outcome:
The
industry trade association used this series of disease specific documents to
explain to non-technical legislative and advocacy stakeholders the value of
new treatments for improving both clinical and economic outcomes, and
educating them about how these treatments were based upon significant
scientific advancements.
|
